Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by elevated pressure in the pulmonary arteries and increased pulmonary vascular resistance. It can lead to right-heart failure and reduced functional capacity. Diagnosis commonly combines clinical assessment with echocardiography, right-heart catheterization, pulmonary function testing, imaging, and laboratory evaluation. Treatment typically involves risk assessment, supportive care, and targeted therapies directed at established disease pathways.

PAH care is shifting toward earlier recognition, structured risk stratification, and combination treatment tailored to disease severity and patient characteristics. Greater attention is being given to connective-tissue-disease-associated PAH, congenital-heart-disease-associated PAH, and other associated forms. Multidisciplinary pathways increasingly connect pulmonology, cardiology, rheumatology, specialized nursing, imaging, rehabilitation, and palliative support. Persistent barriers include delayed referral, uneven access to specialist centers, treatment tolerability, and differences in diagnostic capacity.

Artificial intelligence is being explored for electrocardiogram interpretation, echocardiographic analysis, imaging support, clinical documentation, and identification of patients who may warrant specialist evaluation. Machine-learning models may help combine hemodynamic, functional, imaging, and laboratory variables for more consistent risk assessment, but their clinical value depends on representative training data, external validation, transparent performance reporting, and integration with clinician judgment. Privacy, interoperability, bias monitoring, and regulatory oversight remain essential before routine deployment.

North America generally benefits from established referral networks and specialized PAH centers, although access and affordability remain uneven. Europe is supported by coordinated clinical guidance and specialist expertise, with variation among national reimbursement and referral systems. Asia-Pacific combines advanced programs in some health systems with substantial unmet diagnostic needs elsewhere. Latin America faces challenges involving delayed diagnosis, availability of specialized testing, and continuity of treatment. The Middle East is expanding specialist cardiopulmonary services but shows variation in infrastructure and referral pathways. Africa continues to face limited access to right-heart catheterization, advanced imaging, specialist care, and consistent epidemiologic data, with priorities including earlier recognition and strengthened referral networks.

ASEAN countries are working across diverse health systems, making regional collaboration, workforce development, and referral coordination particularly relevant. BRICS members span substantial differences in diagnostic infrastructure, medicine access, and specialist coverage, emphasizing the value of adaptable care pathways. The European Union benefits from cross-border scientific and policy cooperation, while national implementation and reimbursement remain variable. G7 systems generally possess strong research and specialist capacity but continue to address affordability, aging populations, and equitable access. GCC countries have invested in modern health infrastructure and can further strengthen centralized expertise and coordinated registries. NATO members represent varied health systems, but shared research networks and clinical collaboration can support preparedness and specialist knowledge exchange.

Australia combines specialist respiratory and cardiology expertise with the challenge of serving geographically dispersed populations. Brazil and Mexico continue to require stronger referral pathways and more consistent access beyond major urban centers. Canada and the United States have established specialist programs, while geographic, financial, and insurance-related barriers can affect timely care. China and India are expanding cardiopulmonary capabilities but face wide regional variation in diagnostic access. Japan and South Korea have advanced clinical infrastructure and opportunities to improve early recognition and longitudinal data integration. France, Germany, Italy, Spain, and the United Kingdom benefit from established specialist services, with ongoing attention to referral consistency, capacity, and equitable access. Russia faces variation in specialist availability and diagnostic resources across regions, reinforcing the importance of standardized evaluation and continuity of care.

Leaders should support clinician education that improves recognition of unexplained dyspnea, syncope, exercise limitation, and signs of right-heart strain, particularly in associated conditions. Health systems can strengthen referral protocols, multidisciplinary teams, diagnostic capacity, and longitudinal risk monitoring. Product and evidence strategies should emphasize clinically meaningful outcomes, tolerability, adherence, and applicability across diverse populations. Digital and AI initiatives should use validated datasets, transparent governance, interoperability standards, and prospective evaluation. Partnerships with patient organizations and public-health bodies can improve awareness, shared decision-making, rehabilitation access, and continuity of care.

This executive summary synthesizes established clinical knowledge and publicly documented health-system considerations relevant to PAH. The assessment considers disease recognition, diagnostic practice, treatment pathways, specialist infrastructure, patient-support needs, regional variation, country-level context, and emerging AI applications. Findings are framed qualitatively and avoid market estimates, sizing, shares, forecasts, and company-specific claims. Interpretation should be updated as guidelines, regulatory decisions, clinical evidence, and national health policies evolve.

The PAH landscape is defined by the need to identify disease sooner, confirm diagnosis accurately, assess risk consistently, and sustain individualized care. Regional and national differences in infrastructure, reimbursement, workforce, and referral systems shape outcomes. Artificial intelligence may improve clinical support, but it should complement rather than replace specialist judgment and validated care pathways. Durable progress will depend on coordinated multidisciplinary services, stronger data systems, patient-centered support, and equitable access to evidence-based management.